Palatin Technologies vs Zenas BioPharma
Zenas BioPharma reported revenue of $10 million in fiscal 2025, about the same as Palatin Technologies' $9 million in fiscal 2026. Palatin Technologies had an operating margin of -98.2%, against -3830.6% at Zenas BioPharma. Free cash flow was −$14 million at Palatin Technologies and −$172 million at Zenas BioPharma. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.
Side by side
| Palatin Technologies | Zenas BioPharma | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $9M | $10M |
| Revenue growth | — | 100.0% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | — |
| Operating margin | −98.2% | −3,830.6% |
| Net margin | −94.9% | −3,777.4% |
| Free cash flow | −$14M | −$172M |
| Free cash flow margin | −153.8% | −1,723.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 425.2% | 238.9% |
| Last close | $4.93 | $25.04 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $9,458 | bought $11.4 million, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Palatin TechnologiesZenas BioPharma
Operating margin
Percent of revenue
Palatin TechnologiesZenas BioPharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Palatin TechnologiesZenas BioPharma
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Palatin Technologies and Zenas BioPharma pages.